Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 31, 2020

View Archived Issues

GNOS-PV02 vaccine to be evaluated in patients with HCC

AI-generated compound begins phase I study in Japan for obsessive-compulsive disorder

Inovio and Beijing Advaccine collaborate to advance new vaccine against new coronavirus in China

BREEZE-AD5 phase II study of baricitinib in AD meets primary endpoint

German Medicines Agency approves phase II study of FOL-005

Kedrion Biopharma completes enrollment in phase III CARES10 study

Cerevel starts dosing volunteers in phase I study of CVL-936

First patient dosed in phase Ib study of GMI-1359 in breast cancer

FDA accepts IND application for FS-120 bispecific antibody

BBI-608 plus pembrolizumab shows encouraging antitumor activity in mCRC

Magrolimab plus cetuximab as a promising immunotherapeutic treatment regimen in CRC

Phase II study of PBI-05204 in mPDA does not meet primary endpoint

Fimbrion Therapeutics and GlaxoSmithKline describe Escherichia coli FimH inhibitors

New high affinity nerve growth factor receptor inhibitors identified at Medshine Discovery

Naltrexone prodrugs synthesized at Alkermes

Novartis patents compounds for IKZF2-dependent disease

Recordati Industria Chimica e Farmaceutica discovers P2X3 and P2X2/3 antagonists

"Confused and disorganized": Stress, identity crises part of growing up -- for organoids

RC-48-ADC shows meaningful benefit in phase I solid tumors trial

CEACAM6 levels linked to sensitivity to pelareorep in pancreatic adenocarcinoma

IRICoR, UdeM and Medigene establish collaboration on novel cancer antigens

Phase I study of Rani's orally delivered octreotide meets primary and secondary endpoints

Fuzionaire Diagnostics establishes new research collaboration in neurodegeneration

IND clearance for VistaGen's AV-101 for levodopa-induced dyskinesia in Parkinson's

Immune Response BioPharma plans IND filing for new SARS/coronavirus vaccine

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...